38 / 66
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 3, May/June 2021
148
AFRICA
2016;
118
(11): 1771–1785.
2.
Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs)
and cardiovascular dysfunction: focus on high molecular weight AGEs.
Amino Acids
2017;
49
(9): 1535–1541.
3.
Hu X, Bai T, Xu Z, Liu Q, Zheng Y, Cai L. Pathophysiological funda-
mentals of diabetic cardiomyopathy.
Compr Physiol
2017;
7
(2): 693–711.
4.
Peterson LR, McKenzie CR, Schaffer JE. Diabetic cardiovascular
disease: getting to the heart of the matter.
J Cardiovasc Transl Res
2012;
5
(4): 436–445.
5.
Forbes JM, Cooper ME. Mechanisms of diabetic complications.
Physiol
Rev
2013;
93
(1): 137–188.
6.
Grundy SM, Benjamin IJ, Burke GL,
et al.
Diabetes and cardiovascular
disease: a statement for healthcare professionals from the American
Heart Association.
Circulation
1999;
100
(10): 1134–1146.
7.
Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and
electrolyte disorders.
World J Clin Cases
2014;
2
(10): 488–496.
8.
Sjogren A, Floren CH, Nilsson A. Magnesium deficiency in IDDM
related to level of glycosylated hemoglobin.
Diabetes
1986;
35
(4):
459–463.
9.
Atabek ME, Kurtoglu S, Pirgon O, Baykara M. Serum magnesium
concentrations in type 1 diabetic patients: relation to early atherosclero-
sis.
Diabetes Res Clin Pract
2006;
72
(1): 42–47.
10. Nagase N. Hypertension and serum Mg in the patients with diabetes
and coronary heart disease.
Hypertens Res
1996;
19
( Suppl 1): S65–68.
11. Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM.
Low serum magnesium concentrations are associated with a high preva-
lence of premature ventricular complexes in obese adults with type 2
diabetes.
Cardiovasc Diabetol
2012;
11
23.
12. Morakinyo AO, Samuel TA, Adekunbi DA. Magnesium upregulates
insulin receptor and glucose transporter-4 in streptozotocin-nicotina-
mide-induced type-2 diabetic rats.
Endocr Regul
2018;
52
(1): 6–16.
13. Mubagwa K, Gwanyanya A, Zakharov S, Macianskiene R. Regulation
of cation channels in cardiac and smooth muscle cells by intracellular
magnesium.
Arch Biochem Biophys
2007;
458
(1): 73–89.
14. Amoni M, Kelly-Laubscher R, Blackhurst D, Gwanyanya A. Beneficial
effects of magnesium treatment on heart rate variability and cardiac
ventricular function in diabetic rats.
J Cardiovasc Pharmacol Ther
2017;
22
(2): 169–178.
15. Sameshima H, Ota A, Ikenoue T. Pretreatment with magnesium sulfate
protects against hypoxic-ischemic brain injury but postasphyxial treat-
ment worsens brain damage in seven-day-old rats.
Am J Obstet Gynecol
1999;
180
(3 Pt 1): 725–730.
16. Amoni M, Kelly-Laubscher R, Petersen M, Gwanyanya A.
Cardioprotective and anti-arrhythmic effects of magnesium pretreat-
ment against ischaemia/reperfusion injury in isoprenaline-induced
hypertrophic rat heart.
Cardiovasc Toxicol
2017;
17
(1): 49–57.
17. Buwa CC, Mahajan UB, Patil CR, Goyal SN. Apigenin attenuates beta-
receptor-stimulated myocardial injury via safeguarding cardiac func-
tions and escalation of antioxidant defence system.
Cardiovasc Toxicol
2016;
16
(3): 286–297.
18. Raev DC. Which left ventricular function is impaired earlier in the
evolution of diabetic cardiomyopathy? An echocardiographic study of
young type I diabetic patients.
Diabetes Care
1994;
17
(7): 633–639.
19. Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S.
Abnormal cardiac function in the streptozotocin-diabetic rat. Changes
in active and passive properties of the left ventricle.
J Clin Invest
1990;
86
(2): 481–488.
20. MihmMJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyo-
pathy time dependent echocardiographic evaluation in an experimental
rat model.
Life Sci
2001;
69
(5): 527–542.
21. Wei M, Ong L, Smith MT
, et al.
The streptozotocin-diabetic rat as a
model of the chronic complications of human diabetes.
Heart Lung Circ
2003;
12
(1): 44–50.
22. Liu M, Jeong EM, Liu H
, et al.
Magnesium supplementation improves
diabetic mitochondrial and cardiac diastolic function.
JCI Insight
2019;
4
(1): e123182.
23. Nikolajevic Starcevic J, Janic M, Sabovic M. Molecular Mechanisms
Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients.
Int
J Mol Sci
2019;
20
(5): 1197.
24. Radovits T, Korkmaz S, Matyas C
, et al.
An altered pattern of myocar-
dial histopathological and molecular changes underlies the different
characteristics of type-1 and type-2 diabetic cardiac dysfunction.
J
Diabetes Res
2015;
2015
:
728741.
25. van Heerebeek L, Hamdani N, Handoko ML
, et al.
Diastolic stiffness of
the failing diabetic heart: importance of fibrosis, advanced glycation end
products, and myocyte resting tension.
Circulation
2008;
117
(1): 43–51.
26. Sanyal SN, Wada T, Yamabe M
, et al.
Synaptic degradation of
cardiac autonomic nerves in streptozotocin-induced diabetic rats.
Pathophysiology
2012;
19
(4): 299–307.
27. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-
eclampsia: pharmacokinetic principles.
Clin Pharmacokinet
2000;
38
(4):
305–314.